Faculty, Staff and Student Publications
Publication Date
2-20-2024
Journal
NPJ Vaccines
DOI
10.1038/s41541-024-00821-3
PMID
38378950
PMCID
PMC10879498
PubMedCentral® Posted Date
2-20-2024
PubMedCentral® Full Text Version
Post-print
Abstract
Human cytomegalovirus (HCMV) remains the most common congenital infection and infectious complication in immunocompromised patients. The most successful HCMV vaccine to date, an HCMV glycoprotein B (gB) subunit vaccine adjuvanted with MF59, achieved 50% efficacy against primary HCMV infection. A previous study demonstrated that gB/MF59 vaccinees were less frequently infected with HCMV gB genotype strains most similar to the vaccine strain than strains encoding genetically distinct gB genotypes, suggesting strain-specific immunity accounted for the limited efficacy. To determine whether vaccination with multiple HCMV gB genotypes could increase the breadth of anti-HCMV gB humoral and cellular responses, we immunized 18 female rabbits with monovalent (gB-1), bivalent (gB-1+gB-3), or pentavalent (gB-1+gB-2+gB-3+gB-4+gB-5) gB lipid nanoparticle-encapsulated nucleoside-modified RNA (mRNA-LNP) vaccines. The multivalent vaccine groups did not demonstrate a higher magnitude or breadth of the IgG response to the gB ectodomain or cell-associated gB compared to that of the monovalent vaccine. Also, the multivalent vaccines did not show an increase in the breadth of neutralization activity and antibody-dependent cellular phagocytosis against HCMV strains encoding distinct gB genotypes. Interestingly, peripheral blood mononuclear cell-derived gB-2-specific T-cell responses elicited by multivalent vaccines were of a higher magnitude compared to that of monovalent vaccinated animals against a vaccine-mismatched gB genotype at peak immunogenicity. Yet, no statistical differences were observed in T cell response against gB-3 and gB-5 variable regions among the three vaccine groups. Our data suggests that the inclusion of multivalent gB antigens is not an effective strategy to increase the breadth of anti-HCMV gB antibody and T cell responses. Understanding how to increase the HCMV vaccine protection breadth will be essential to improve the vaccine efficacy.
Keywords
RNA vaccines, Herpes virus
Published Open-Access
yes
Recommended Citation
Wang, Hsuan-Yuan; Li, Leike; Nelson, Cody S; et al., "Multivalent Cytomegalovirus Glycoprotein B Nucleoside Modified mRNA Vaccines Did Not Demonstrate a Greater Antibody Breadth" (2024). Faculty, Staff and Student Publications. 1707.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/1707
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Cardiovascular Diseases Commons, Influenza Humans Commons, Influenza Virus Vaccines Commons, Medical Genetics Commons, Medical Microbiology Commons, Oncology Commons